Clinical significance of 4 L lymphadenectomy in solid dominant clinical stage I non-small cell lung cancer in the left upper lobe

被引:0
作者
Watanabe, Yukio [1 ]
Hattori, Aritoshi [1 ]
Fukui, Mariko [1 ]
Matsunaga, Takeshi [1 ]
Takamochi, Kazuya [1 ]
Suzuki, Kenji [1 ]
机构
[1] Juntendo Univ, Sch Med, Dept Gen Thorac Surg, 1-3 Hongo 3 Chome,Bunkyo Ku, Tokyo 1138421, Japan
关键词
non-small cell lung cancer; clinical stage I; solid dominant; 4 L lymphadenectomy; LYMPH-NODE DISSECTION; SURVIVAL; SURGERY;
D O I
10.1093/jjco/hyaf032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The significance of station 4 L lymph node dissection (LND) for early-stage non-small cell lung cancer (NSCLC) is unknown. Methods: We evaluated 342 patients who underwent complete anatomical resection and mediastinal LND for radiologically solid dominant clinical (c)-Stage I left upper lobe NSCLC between 2008 and 2022. Solid dominant was defined as a consolidation tumor ratio >0.5, on thin-section computed tomography. After matching, postoperative complications and outcomes between the 4 L LND and non-4 L LND groups were compared. Predictors of 4 L metastasis was also identified using logistic regression analysis. Results: 4LND was performed in 215 patients (63%), and 4 L metastasis was detected in 11 patients. Matching yielded 108 pairs. Recurrent nerve paralysis was more frequent in the 4LND group (P = 0.02) with no significant differences in the overall survival (OS) (5y OS: 85.2% vs. 86.3%, P = 0.66) and recurrence-free survival (RFS) (5y RFS: 78.4% vs. 78.5%, P = 0.51) between the 4 L LND and non-4 L LND groups. Logistic regression analysis determined solid component size >20 mm (P = 0.02) and pleural indentation (P = 0.02) on computed tomography findings as clinical risk factors for 4 L metastasis. The predictive criteria for 4 L metastasis were defined as solid component size <= 20 mm without pleural indentation (specificity: 100%, positive predictive value: 100%). Conclusions: 4 L LND had a higher frequency of recurrent nerve palsy, although no survival improvement was observed in solid dominant c-Stage I left upper NSCLC. 4 L LND may be omitted for solid component size <= 20 mm without pleural indentation.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Clinical factors and prognosis in non-small cell lung cancer
    Martins, SJ
    Pereira, JR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05): : 453 - 457
  • [42] A lobe-specific lymphadenectomy protocol for solitary pulmonary nodules in non-small cell lung cancer
    Yang, Xue-Ning
    Zhao, Ze-Rui
    Zhong, Wen-Zhao
    Nie, Qiang
    Liao, Ri-Qiang
    Dong, Song
    CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (06) : 538 - 544
  • [43] Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis
    Meng, Di
    Zhou, Zhenyu
    Wang, Yiqing
    Wang, Luming
    Lv, Wang
    Hu, Jian
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 50 (04) : 597 - 604
  • [44] Mathematical models for intraoperative prediction of metastasis to regional lymph nodes in patients with clinical stage I non-small cell lung cancer
    Zhou, Yue
    Du, Junjie
    Ma, Changhui
    Zhao, Fei
    Li, Hai
    Ping, Guoqiang
    Wang, Wei
    Luo, Jinhua
    Chen, Liang
    Zhang, Kai
    Zhang, Shijiang
    MEDICINE, 2022, 101 (42) : E30362
  • [45] Clinical significance of the 'not otherwise specified' subtype in candidates for resectable non-small cell lung cancer
    Tane, Shinya
    Nishio, Wataru
    Ogawa, Hiroyuki
    Hokka, Daisuke
    Tane, Kenta
    Tanaka, Yugo
    Tauchi, Shunsuke
    Uchino, Kazuya
    Sakai, Yasuhiro
    Ohbayashi, Chiho
    Yoshimura, Masahiro
    Maniwa, Yoshimasa
    ONCOLOGY LETTERS, 2014, 8 (03) : 1017 - 1024
  • [46] Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer
    Jeremic, B
    Shibamoto, Y
    Acimovic, L
    Milisavljevic, S
    RADIOTHERAPY AND ONCOLOGY, 1999, 51 (02) : 141 - 145
  • [47] Comparison of lobe-specific mediastinal lymphadenectomy versus systematic mediastinal lymphadenectomy for clinical stage T1aN0M0 non-small cell lung cancer
    Ma, Wei
    Zhang, Zhen-Jiang
    Li, Yun
    Ma, Guo-Yuan
    Zhang, Lin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2013, 9 (05) : S101 - S105
  • [48] Treatment of stage I non-small cell lung cancer: What's trending?
    McMurry, Timothy L.
    Shah, Puja M.
    Samson, Pamela
    Robinson, Clifford G.
    Kozower, Benjamin D.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2017, 154 (03) : 1080 - 1087
  • [49] The prognostic impact of tumor volume on stage I non-small cell lung cancer
    Su, Xiao-Dong
    Xie, Hao-Jun
    Liu, Qian-Wen
    Mo, Yun-Xian
    Long, Hao
    Rong, Tie-Hua
    LUNG CANCER, 2017, 104 : 91 - 97
  • [50] A clinical model to estimate recurrence rusk in resected stage I non-small cell lung cancer
    Goodgame, Boone
    Hiswanathan, Avinash
    Miller, Ryan
    Gao, Feng
    Meyers, Bryan
    Battafarano, Richard J.
    Patterson, Alexander
    Cooper, Joel
    Guthrie, Tracey J.
    Bradley, Jeffrey
    Pillot, Giancarlo
    Govindan, Ramaswamy
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (01): : 22 - 28